Shinji Yamazaki

List of Publications by Citations

20 papers	331 citations	9 h-index	18 g-index
20 ext. papers	414 ext. citations	4.3 avg, IF	3.57 L-index

#	Paper	IF	Citations
20	Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. *Drug Metabolism and Disposition*, **2008**, 36, 1267-74	4	89
19	Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. *Drug Metabolism and Disposition*, **2011**, 39, 383-93	4	47
18	Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. *AAPS Journal*, **2013**, 15, 354-66	3.7	40
17	Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model. *Drug Metabolism and Disposition*, **2015**, 43, 1417-29	4	34
16	Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 351, 67-76	4.7	23
15	Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase. *Drug Metabolism and Disposition*, **2015**, 43, 54-62	4	20
14	Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 634-642	4.5	20
13	Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies. *Clinical Cancer Research*, **2017**, 23, 1080-1090	12.9	17
12	Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. *Drug Metabolism and Disposition*, **2018**, 46, 1200-1211	4	10
11	Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 253-65	5.5	8
10	Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. *Drug Metabolism and Disposition*, **2004**, 32, 398-404	4	6
9	Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**,	4.5	3
8	SAM Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. *Molecular Cancer Therapeutics*, **2021**,	6.1	3
7	Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 373, 220-229	4.7	2
6	Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters. *Journal of Clinical Pharmacology*, **2018**, 58, 1053-1060	2.9	2
5	Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride in rats. *Drug Metabolism and Disposition*, **2009**, 37, 937-45	4	2
4	Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**, 10, 1018-1031	4.5	2

3	Translational Modeling and Simulation for Molecularly Targeted Small Molecule Anticancer Agents: Case Studies of Multiple Tyrosine Kinase Inhibitors, Crizotinib and Lorlatinib. *Methods and Principles in Medicinal Chemistry*, **2018**, 433-466	0.4	1
2	A retrospective analysis of actionable pharmacogenetic/genomic biomarker language in FDA labels. *Clinical and Translational Science*, **2021**, 14, 1412-1422	4.9	1
1	Evaluation of Prediction Accuracy for Volume of Distribution in Rat and Human Using In‐Vitro, In‐Vivo, PBPK and QSAR Methods. *Journal of Pharmaceutical Sciences*, **2021**, 110, 1799-1823	3.9	1